Maria S Altieri1, Jie Yang2, Janos Hajagos3, Konstantinos Spaniolas4, Jihye Park5, Antonios P Gasparis6, Andrew T Bates4, Salvatore Docimo4, Mark Talamini4, A Laurie Shroyer7, Aurora D Pryor4. 1. Division of Bariatric, Foregut and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, Stony Brook University, 100 Nichols Road, HSC T19, Stony Brook, NY, 11794, USA. maria.altieri@stonybrookmedicine.edu. 2. Department of Family, Population and Preventive Medicine, Stony Brook University Medical Center, Stony Brook University, Stony Brook, NY, USA. 3. Department of Biomedical Informatics, Stony Brook University Medical Center, Stony Brook University, Stony Brook, NY, USA. 4. Division of Bariatric, Foregut and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, Stony Brook University, 100 Nichols Road, HSC T19, Stony Brook, NY, 11794, USA. 5. Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, USA. 6. Division of Vascular and Endovascular Surgery, Department of Surgery, Stony Brook University Medical Center, Stony Brook University, Stony Brook, NY, USA. 7. Department of Surgery, Stony Brook University Medical Center, Stony Brook University, Stony Brook, NY, USA.
Abstract
BACKGROUND: Studies examining utilization and impact of venous thromboembolism (VTE) chemoprophylaxis for patients undergoing bariatric surgery are limited. Determination of the optimal prophylactic regimen to minimize complications is crucial. METHODS: The Cerner Health Facts database from 2003 to 2013 was queried using ICD-9 codes to identify patients undergoing laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (RYGB). VTE chemoprophylaxis regimens were divided into pre-operative alone (PreP), post-operative alone (PostP), both pre-operative and post-operative (PPP), or no prophylaxis (NP). Specific chemoprophylaxis agents were compared. Comparisons in inpatient clinical outcomes were based on univariate analysis and multivariable logistic regression when appropriate. RESULTS: We identified 11,860 patients who underwent LSG and RYGB. 634 (5.35%) had PreP, 4593 (38.73%) had PostP, 2646 (22.31%) had PPP, and 3987 (33.62%) had NP. The overall rates of transfusion, DVT, and PE were 2.48, 0.27, and 0.18%, respectively. Patients without chemoprophylaxis had higher rate of DVT compared to any chemoprophylaxis (0.58 vs 0.11%, p < 0.0001), without any significant difference in PE rate. Patients with pre-operative chemoprophylaxis were more likely to receive transfusion compared to patients with post-operative prophylaxis alone (OR 1.98, 95% CI 1.28-3), without significant difference in having VTE. When examining heparin versus enoxaparin versus mixed regimen in the PostP group, mixed regimen was associated with increased transfusion requirements (p < 0.001). CONCLUSIONS: Bariatric surgical VTE chemoprophylaxis utilization is inconsistent. In this study, post-operative VTE chemoprophylaxis was associated with decreased VTE events compared to NP, while minimizing bleeding compared to PreP. Mixed therapy using heparin and enoxaparin was associated with more bleeding.
BACKGROUND: Studies examining utilization and impact of venous thromboembolism (VTE) chemoprophylaxis for patients undergoing bariatric surgery are limited. Determination of the optimal prophylactic regimen to minimize complications is crucial. METHODS: The Cerner Health Facts database from 2003 to 2013 was queried using ICD-9 codes to identify patients undergoing laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (RYGB). VTE chemoprophylaxis regimens were divided into pre-operative alone (PreP), post-operative alone (PostP), both pre-operative and post-operative (PPP), or no prophylaxis (NP). Specific chemoprophylaxis agents were compared. Comparisons in inpatient clinical outcomes were based on univariate analysis and multivariable logistic regression when appropriate. RESULTS: We identified 11,860 patients who underwent LSG and RYGB. 634 (5.35%) had PreP, 4593 (38.73%) had PostP, 2646 (22.31%) had PPP, and 3987 (33.62%) had NP. The overall rates of transfusion, DVT, and PE were 2.48, 0.27, and 0.18%, respectively. Patients without chemoprophylaxis had higher rate of DVT compared to any chemoprophylaxis (0.58 vs 0.11%, p < 0.0001), without any significant difference in PE rate. Patients with pre-operative chemoprophylaxis were more likely to receive transfusion compared to patients with post-operative prophylaxis alone (OR 1.98, 95% CI 1.28-3), without significant difference in having VTE. When examining heparin versus enoxaparin versus mixed regimen in the PostP group, mixed regimen was associated with increased transfusion requirements (p < 0.001). CONCLUSIONS: Bariatric surgical VTE chemoprophylaxis utilization is inconsistent. In this study, post-operative VTE chemoprophylaxis was associated with decreased VTE events compared to NP, while minimizing bleeding compared to PreP. Mixed therapy using heparin and enoxaparin was associated with more bleeding.
Authors: David A Froehling; Paul R Daniels; Karen F Mauck; Maria L Collazo-Clavell; Aneel A Ashrani; Michael G Sarr; Tanya M Petterson; John A Heit Journal: Obes Surg Date: 2013-11 Impact factor: 4.129
Authors: Michael K Gould; David A Garcia; Sherry M Wren; Paul J Karanicolas; Juan I Arcelus; John A Heit; Charles M Samama Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Mohammad H Jamal; Ricard Corcelles; Hideharu Shimizu; Mathew Kroh; Fernando M Safdie; Raul Rosenthal; Stacy A Brethauer; Philip R Schauer Journal: Surg Endosc Date: 2014-07-02 Impact factor: 4.584
Authors: Michel Gagner; Faith Selzer; Steve H Belle; Marc Bessler; Anita P Courcoulas; Gregory F Dakin; Dan Davis; William B Inabnet; James E Mitchell; Alfons Pomp; Gladys W Strain; Walter J Pories; Bruce M Wolfe Journal: Surg Obes Relat Dis Date: 2012-07-31 Impact factor: 4.734
Authors: Jonathan F Finks; Wayne J English; Arthur M Carlin; Kevin R Krause; David A Share; Mousumi Banerjee; John D Birkmeyer; Nancy J Birkmeyer Journal: Ann Surg Date: 2012-06 Impact factor: 12.969